Kura Oncology (KURA) CLO reports PSU vesting and share sale

Rhea-AI Filing Summary

Kura Oncology, Inc. (KURA) reported insider equity activity by its Chief Legal Officer on a Form 4. On 11/13/2025, 48,900 shares of common stock were acquired at a price of $0, reflecting vesting tied to performance-based restricted stock units (PSUs). On 11/14/2025, 8,804 shares were sold at $11.1769 in a sell-to-cover transaction for taxes related to this vesting. These PSUs were granted on May 31, 2023 and vest based on specified development milestones and continued service. Following the reported transactions, the officer beneficially owned 188,139 shares of Kura Oncology common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bair Teresa Brophy

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/13/2025		A		48,900	A	$0	196,943	D
Common Stock	11/14/2025		S(1)		8,804	D	$11.1769	188,139	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares.

	/s/ Teresa Bair	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kura Oncology (KURA) disclose in this Form 4?

The filing shows that Kura Oncology's Chief Legal Officer acquired 48,900 shares of common stock at $0 on 11/13/2025 through the vesting of performance-based restricted stock units and sold 8,804 shares at $11.1769 on 11/14/2025 in a sell-to-cover transaction for taxes.

Who is the reporting person in the Kura Oncology (KURA) Form 4 and what is their role?

The reporting person is Teresa Bair, who is identified as an Officer of Kura Oncology with the title Chief Legal Officer.

How many Kura Oncology (KURA) shares does the insider own after the reported transactions?

After the reported acquisition and sale transactions, the Chief Legal Officer beneficially owned 188,139 shares of Kura Oncology common stock in direct ownership.

What triggered the vesting of performance-based restricted stock units in Kura Oncology (KURA)?

The vesting was triggered when the performance criteria for one specified development milestone were determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying PSU shares originally granted on May 31, 2023.

Why were 8,804 Kura Oncology (KURA) shares sold in this Form 4?

The 8,804 shares were sold under transaction code S as a sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units.

What type of equity award is involved in the Kura Oncology (KURA) Form 4?

The transaction involves performance-based restricted stock units (PSUs), where each PSU represents the contingent right to receive one share of Kura Oncology common stock based on specified development milestones and continued service through each vesting date.

Is the Kura Oncology (KURA) Form 4 filed by one or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person, not by a group.